Background Characterisation of risk groups who may benefit from pneumococcal
vaccination is essential for the generation of recommendations and policy. Methods We …

Within the European Union (EU), documenting the burden of invasive pneumococcal
disease (IPD) in infants and children is important for coordinating effective pneumococcal …

Background: Since the introduction of childhood pneumococcal conjugate vaccines,
invasive pneumococcal disease (IPD) incidence has decreased in children and the …

OBJECTIVES: Children with underlying conditions remain at increased risk for invasive
pneumococcal diseases (IPD). This study describes the epidemiology, serotype distribution …

Background Invasive pneumococcal disease (IPD) has declined significantly since the
introduction of pneumococcal conjugate vaccines (PCVs). It is not known whether certain …

High incidence of childhood invasive pneumococcal disease (IPD) in the US declined
steeply after 7-valent pneumococcal conjugate vaccine (PCV7) introduction, outweighing …

Background: In England and Wales, replacement of childhood 7-valent pneumococcal
conjugate vaccine (PCV7) with a 13-valent vaccine (PCV13) in 2010 was associated with a …

Risk factors for invasive pneumococcal disease (IPD) include young and old age,
comorbidities (such as splenic dysfunction, immunodeficiencies, chronic renal disease …

Background Streptococcus pneumoniae is a leading cause of invasive infection in young
children causing morbidity and mortality. Active surveillance systems of invasive …

Background: Invasive pneumococcal disease (IPD) is associated with significant morbidity
and mortality in children. Universal pneumococcal conjugate vaccination has changed the …